Telemonitoring and Connected Care Applied to Multiple Sclerose
MonSter Study, Telemonitoring and Connected Care Applied to Multiple Sclerose
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- MSmonitor, a self-management/education program with e-health interventions
- Video calling program "Better-close"
- Researchmanager program
What it measured
Main measures
The primary endpoint is Multiple Sclerose Quality of Life (MSQuol54)
2 years
Quality of life (reported by participants)
Other measures (7)
Impact on participation and autonomy (IPA)
2 years
Work together on health (PIH)
2 years
Health questionnaire (Eq5D-5L)
2 years
Walking and mobilityPainMood and sleepQuality of life (reported by participants)MS Self-Efficacy Scale (MSSES)
2 years
Medical Consumption Questionnaire (iMCQ)
2 years
Productivity Costs Questionnaire (iPCQ)
2 years
Patient satisfaction questionnaire (PTO)
2 years
Quality of life (reported by participants)
Who could take part
MS (type not specified) · 18 and over
Show the full criteria
Inclusion criteria
The participant is an MS patient who is being treated within the Isala. Is 18 years of age or older Has digital skills The caregiver is the caregiver of an MS patient Is older than 18 years
Exclusion criteria
The patient does not master the Dutch language. The patient has insufficient computer skills. Disabled adults are excluded from the study.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The investigators designed a new care concept based on a multi-modal version of the MSmonitor program, the 'MSmonitor-Plus and Video Calling Care' (MPVC). MPVC combines the self-management and education program MSmonitor with video consultations by using specific questionnaires designed for high-frequency/intensive self-assessments of MS patients. 'The overall objective of this study is to assess the feasibility and (cost)-effectiveness of MPVC compared to Care as Usual (CAU). An RCT with two parallel groups will be conducted to compare the MPVC with a CAU in MS patients and their caregivers. In this study, 208 MS patients will be included with follow-up measurements for two years (at baseline and every three months). After randomization, 104 patients will be assigned to MPVC and 104 patients to CAU. The study will consist of three parts: 1) a clinical effectiveness study, 2) a cost-effectiveness study, and 3) process evaluation.
Papers
Loading reviews and guidelines…
History
Started
Apr 2021
Main results due
Apr 2024
Finished
Dec 2025